Huron Consulting Group delivered the beat-and-raise quarter its rally demanded, but the details are less clean than the headline. Adjusted EPS of $2.62 topped the $2.47 consensus by 6.1% and grew 24.8% year over year. Revenue of $491.45 million beat expectations by 2.4% and rose 11.4%. Management lifted the midpoint of full-year adjusted EPS guidance to $9.30, now a $9.20-$9.40 range. That is the central tension: profitability is clearly improving, while top-line growth, the Commercial segment and cash conversion all moved the wrong way.

The quality of the beat deserves scrutiny. Revenues before reimbursable expenses rose 11.6% to a record $482.5 million, but $21.1 million came from acquisitions. Organic growth was 6.7%, below the 8.2% year-to-date pace, and total growth slowed from 15.7% in the second quarter.

The EPS line also benefited heavily from capital deployment. Adjusted net income grew 14.1%, well short of the 24.8% per-share gain. The gap reflects a diluted share count that fell to 16.3 million from 17.8 million after Huron repurchased about 10% of its stock this year. Much of that buyback was debt-funded, with long-term debt climbing to $794 million from $490 million at year-end.

GAAP EPS rose only 2.3% to $1.75. That figure absorbed a $0.36 hit from a non-cash credit loss on a convertible debt investment, plus a $4.9 million contingent-consideration charge. Management attributed the contingent-consideration charge to acquired businesses outperforming their original assumptions, which is arguably a high-class problem.

Margins are the genuine bright spot. Adjusted EBITDA margin reached 16.0%, an eight-year quarterly high. Utilization rose to 76.2% in Consulting and 81.2% in Digital. Education was the standout: segment operating income jumped 21% on just 6.6% revenue growth, and margin reached 29.1%. Management said Education is tracking at or above the top of its 24%-26% target. Healthcare grew 16.5%, and Healthcare managed services revenue nearly doubled to $48.9 million, with a third straight quarter of 40%-plus organic growth.

Beneath those numbers, however, momentum cooled:

• Healthcare organic growth slowed to 9% from 12% in the second quarter.
• Commercial revenue growth collapsed to 6.4% from 24.6%. Organic Commercial growth was only low single digits, and Commercial digital fell 1% amid slower conversion of AI projects.
• Commercial margin fell to 13.9% from 21.0% in the prior quarter. Management cut the segment's full-year outlook to low-double-digit growth at the low end of its 19%-21% margin range.

Utilization near its ceiling also limits how much more efficiency can carry earnings.

The weakest disclosure was cash. Management cut full-year free cash flow guidance to $150-$170 million from $180-$220 million, a range it had held on the two prior calls. It cited a revised payment schedule on a multi-year engagement and a heavier mix of performance-fee work. Days sales outstanding rose to 83 from 79. Year-to-date operating cash flow was just $15.3 million versus $67.0 million a year earlier, as unbilled services swelled by $64 million. Revenue guidance was merely narrowed to $1.855-$1.885 billion with an unchanged midpoint, trimming the top end, and the 14.5%-15.0% EBITDA margin outlook was only affirmed. Bears have legitimate ammunition here: earnings are being recognized faster than they are being collected.

The forward story still has credible supports:

• Trailing six-month bookings are up more than 20%.
• AI involvement in digital bookings rose above 65%, from about 60% in the first half and roughly 50% a year ago.
• Management framed 2027 Medicaid changes under the OBBBA as a demand driver and expects a very strong healthcare year.
• RelateCare cross-sell synergies are just beginning.
• Huron is investing about $2.2 million per quarter in Commercial talent, targeting above-average Commercial growth in 2027.
• A $200 million buyback increase leaves $265.9 million available.
• Leverage eased to 2.6x from 2.8x.
• The effective tax rate outlook was lowered to 27%-29%.

The market setup is more complicated than the surprise implies. Shares entered the report at $195, up 45.4% from the $134.09 open after the July release. That price sits 40.7% above the 200-day moving average and about 4% below the 52-week high of $203.37 set on October 23. Investor sentiment, meanwhile, remained negative and was essentially unchanged, edging from -0.33 to -0.32. The Earnings Whispers trend readings are uniformly positive, consistent with the strength of the run. Still, a stock priced this close to its highs leaves little room for a quarter featuring decelerating organic growth and a cash-flow cut.

The bottom line is that Huron's margin expansion, Healthcare managed-services surge and higher EPS guidance keep the earnings story intact. However, the headline beat leaned on buybacks, acquisitions and near-peak utilization. Slowing organic growth, a stumbling Commercial segment and a roughly $40 million free-cash-flow cut are the issues to watch. After a 45% run, the burden now shifts to proving that 2027 demand and cash conversion can catch up with reported profits.